Innopharmax Inc

Innopharmax Inc has a market price of 14.3 TWD per share and a market capitalization of 1,709,929,650 TWD, with a price-to-book ratio of 4.08 and a price-to-tangible-book ratio of 4.08. The company's liquidity position is characterized by a current ratio of 3.52 and cash and equivalents of 97,280,000 TWD, indicating a strong short-term liquidity position. The company's debt-to-equity ratio is 0.03, suggesting a low level of leverage. In terms of profitability, Innopharmax Inc reported a net income of -184,398,000 TWD and an operating income of -171,837,000 TWD, indicating a significant loss for the period. The company's return on equity is -0.4399 and return on assets is -0.3932, both of which are negative, suggesting poor returns on invested capital. The company's gross profit of 9,831,000 TWD is significantly lower than its revenue of 68,987,000 TWD, indicating high cost of goods sold. Innopharmax Inc's revenue is primarily concentrated in Taiwan and Mainland China, with no other geographic regions disclosed in the input data. The company's product portfolio includes BESTNEM, GADOMNI, Innomustine, Immurin, and Inpheno Tablets, covering multiple therapeutic areas such as anti-infective medications, contrast agents, cancer treatments, immunotherapy drugs, and medicines for rare diseases. The company's growth trajectory is currently negative, with a net income of -184,398,000 TWD and an operating income of -171,837,000 TWD. The company's revenue of 68,987,000 TWD is lower than the analyst estimate of 33,791,000 TWD, indicating a potential decline in revenue. The company's capital expenditure of -276,000 TWD is minimal, suggesting limited investment in new projects. Innopharmax Inc's risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's operating cash flow of -134,192,000 TWD and free cash flow of -178,349,000 TWD are both negative, indicating a cash outflow. The company's dilution potential is low, with shares outstanding basic and diluted both at 119,575,500. Recent events for Innopharmax Inc include the last actual EPS of -2.87 TWD and the last actual revenue of 33,791,000 TWD, both of which are below the company's reported figures. The company's financial performance is currently in a downturn, with significant losses and negative cash flows.